Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Quince Therapeutics, Inc. (CRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/24/2023 8-K Quarterly results
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/05/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on April 5, 2023",
"Rights Agreement, between Quince Therapeutics, Inc. and American Stock Transfer & Trust Company, LLC, which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C",
"Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan"
03/28/2023 8-K Quarterly results
01/30/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events &nbs...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/27/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/16/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/01/2022 8-K Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Othe...
Docs: "Certificate of Amendment to the registrant’s Certificate of Incorporation, effective August 1, 2022",
"Amended and Restated Bylaws",
"Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name"
07/22/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/12/2022 8-K Director compensation was amended/approved
Docs: "Agreement and Plan of Merger and Reorganization, by and among Cortexyme, Inc., Novosteo Inc., Quince Merger Sub I, Inc., Quince Merger Sub II, LLC and Fortis Advisors LLC"
05/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cortexyme Announces Agreement to Acquire Novosteo"
05/02/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
03/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/02/2022 8-K Quarterly results
01/26/2022 8-K Other Events  Interactive Data
12/23/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Legal Opinion of Cooley LLP",
"Open Market Sale AgreementSM dated December 23, 2021, by and between Cortexyme, Inc. and Jefferies LLC"
10/26/2021 8-K Other Events  Interactive Data
06/17/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/18/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
01/26/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones"
01/25/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 19, 2021 CORTEXYME, INC. Delaware 001-38890 90-1024039 269 East Grand Ave. South San Francisco, California 94080 Registrant's telephone number, including area code: 910-5717 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ..."
12/04/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 4, 2020 CORTEXYME, INC. Delaware 001-38890 90-1024039 269 East Grand Ave. South San Francisco, California 94080 Registrant's telephone number, including area code: 910-5717 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ..."
06/10/2020 8-K Submission of Matters to a Vote of Security Holders
05/21/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Executive Change in Control and Severance Agreement"
05/12/2020 8-K Quarterly results
04/30/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/17/2020 8-K Quarterly results
02/06/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Stock Purchase Agreement",
"Cortexyme Announces $125 Million Private Placement SOUTH SAN FRANCISCO, Calif. - February 5, 2020 - Cortexyme, Inc. , a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, today announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company's Board of Directors in connection with a private placement of its common stock. The transaction is expected to result in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company plans to use the net proceeds from the private placement primarily to advance clinical development, as well as for gen..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy